Novozymes finalizes sale of Novozymes Biopharma Sweden

Novozymes has today finalized the sale of Novozymes Biopharma Sweden, located in Lund, Sweden, to American-owned Repligen Corp.

​As communicated in the press release on October 27th regarding the divestment of Novozymes Biopharma Sweden, Novozymes expected to finalize the deal in the fourth quarter of 2011. Today, the sale has been finalized.

Novozymes Biopharma Sweden is a small part of Novozymes’ Biopharma business.

See the previous announcement here.